Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company developing Wnt pathway–modulating therapeutics with a focus on severe eye diseases, and its news flow reflects this ophthalmology and research orientation. Company press releases frequently highlight progress in its retinal disease pipeline, including updates on preclinical data for candidates such as SZN-8141, SZN-8143, and SZN-413, as well as plans related to regulatory milestones like an intended Investigational New Drug (IND) application for SZN-8141.
Investors following SRZN news can expect regular business updates tied to quarterly financial results, where Surrozen discusses research service revenue, operating expenses, and non-cash items alongside narrative commentary on pipeline momentum. These reports often describe how the company is leveraging its Wnt biology expertise and antibody technologies to advance programs in retinal vascular diseases.
Surrozen’s news stream also covers scientific and medical conference activity. The company reports presentations at ophthalmology-focused meetings such as the Association for Research in Vision and Ophthalmology (ARVO), Clinical Trials at the Summit, and various healthcare investor conferences. These announcements may include summaries of preclinical findings on Wnt-mediated retinal vascular repair and regeneration, as well as overviews of next-generation Wnt therapeutics in retinal diseases.
Corporate and governance developments are another recurring theme in SRZN news. Surrozen discloses leadership changes, including appointments to key roles like Chief Financial Officer and Vice President of Clinical Development, and reports inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Updates on intellectual property, such as the issuance of U.S. patents related to its SWAP™ technology for multi-specific Wnt surrogates, and collaboration developments, including changes to related-party research agreements and details of its partnership with Boehringer Ingelheim, also appear in its announcements. For readers tracking SRZN, this news page aggregates these financial, scientific, and corporate updates in one place.
Surrozen (NASDAQ: SRZN) has been granted U.S. Patent No. 12,297,278 for its SWAP™ technology, expanding its intellectual property portfolio in Wnt pathway therapeutics. The patent covers tetravalent, multi-specific Wnt surrogates that utilize antibody-based molecules to target key receptors in the Wnt pathway.
The company's patent portfolio now includes 6 U.S. patents, 10 international patents, and multiple pending applications. The newly granted patent specifically covers technology involving two Frizzled (Fzd) binding regions and two LRP5/6 binding regions, connected via linker moieties. Surrozen has demonstrated that multivalent binding to Fzd and LRP is crucial for maximal signaling through selective surrogate Wnt molecules.
Surrozen (SRZN) reported its Q4 and full year 2024 financial results, highlighting a strategic focus on ophthalmology pipeline programs. The company secured a two-tranche financing of $175M in gross proceeds to fund multiple ophthalmology programs through Phase 1 studies.
Key financial metrics for 2024 include:
- Cash position of $34.6M as of December 31, 2024
- Additional gross proceeds of $76.4M from March 2025 financing
- Collaboration revenue of $10M from BI milestone
- Research and development expenses decreased to $21.1M from $27.2M in 2023
- Net loss increased to $63.6M compared to $43M in 2023
The company received confirmation that Boehringer will advance SZN-413 toward clinical testing and completed a research collaboration with TCGFB for antibody development targeting TGF-β.
Surrozen (NASDAQ: SRZN) announced a strategic shift to focus on ophthalmology programs, supported by an oversubscribed $175 million private placement. The funding will advance multiple eye disease treatments through Phase 1 studies.
The company's two lead candidates for retinopathies are SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6), targeting conditions like AMD, diabetic retinopathy, and other severe eye diseases. Both compounds have shown promise in preclinical models by stimulating Wnt signaling and promoting normal retinal vessel growth while inhibiting pathological vessel development.
Surrozen will discontinue the development of SZN-043 for severe alcohol-associated hepatitis, despite its safety profile, due to insufficient early clinical benefit signals. The private placement consists of two tranches: an initial $70 million closing around March 26, 2025, and a second $105 million tranche contingent on FDA clearance of the SZN-8141 IND, expected in 2026.
Surrozen (Nasdaq: SRZN), a biotech company focused on targeted therapeutics that activate the Wnt pathway for tissue repair, has announced its participation in two major healthcare investor conferences. CEO Craig Parker will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 13, 2024, with a fireside chat at 3:00 PM ET, and at the Stifel 2024 Healthcare Conference on November 19, 2024, presenting at 2:25 PM ET. Live audio webcasts will be available through Surrozen's investor website, with recordings archived for later access.
Surrozen reported Q3 2024 financial results with significant progress in its clinical programs. The company received a $10 million milestone payment from Boehringer Ingelheim for SZN-413 development. Key highlights include substantial enrollment in the Phase 1b trial of SZN-043 for severe alcohol-associated hepatitis, with proof-of-concept data expected in H1 2025. The first cohort showed no drug-related serious adverse events and potential clinical benefits. The company reported Q3 revenue of $10 million and a net loss of $1.4 million, with cash position at $31 million as of September 30, 2024.
Surrozen (SRZN) has announced a strategic research collaboration with TCGFB to develop antibody therapeutics targeting TGF-β for treating idiopathic pulmonary fibrosis (IPF). Under the two-year agreement, Surrozen will provide antibody discovery services while TCGFB will retain all TGF-β product-related intellectual property. In compensation, TCGFB will pay Surrozen up to $6 million plus third-party costs and issue a warrant for up to 3,380,000 shares of TCGFB common stock at $0.0001 per share, subject to vesting conditions.
Surrozen (Nasdaq: SRZN) has announced a $10 million milestone payment from Boehringer Ingelheim as part of their collaboration on retinal diseases. Boehringer is advancing the development of SZN-413, a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wnt signaling, designed using Surrozen's SWAP™ technology.
SZN-413 offers the potential to restore retinal function in patients with retinal vascular diseases, which affect nearly 150 million people globally. Preclinical data suggest that SZN-413 could stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.
Craig Parker, President and CEO of Surrozen, expressed excitement about Boehringer's decision to proceed with SZN-413's development, highlighting the strong evidence supporting Fzd-4 specific Wnt signaling's role in retinal vasculature.
Surrozen (Nasdaq: SRZN) reported Q2 2024 financial results and business updates. Key highlights include:
- Ongoing enrollment in SZN-043 Phase 1b trial for Severe Alcoholic Hepatitis
- Presented first-in-human data from SZN-043 Phase 1a trial at EASL
- Published study on Targeted Protein Degradation technologies
- Cash position: $37.8 million as of June 30, 2024
- R&D expenses: $5.3 million, down from $6.9 million in Q2 2023
- Net loss: $25.3 million, up from $9.4 million in Q2 2023
The company anticipates proof-of-concept data from the SZN-043 Phase 1b trial in H1 2025 and potential nomination of a lead Fzd-4 targeted Wnt agonist development candidate in 2024, which could trigger a $10 million milestone payment from Boehringer Ingelheim.
Surrozen (Nasdaq: SRZN) has published new data in eLife demonstrating the potential of its proprietary SWEETS platform to enhance Wnt signaling. The study highlights the development of two new ASGR-targeted SWEETS bispecific antibodies that improve Wnt-signal activation through a unique protein degradation platform. This innovation offers promising new avenues for treating liver diseases by promoting cell-specific regenerative therapeutics. Additionally, Surrozen released a review in iScience detailing advancements in Wnt-activating technologies, underscoring the significant progress in the field and its potential to address various tissue degenerative diseases.